Page 8 - David Ricks News Today

Explosive demand and increased manufacturing capacity for Eli Lillys weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 6%.

BioPharma

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.

Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife for my appearance,” says Rajput. The drugs — Wegovy and Ozempic — which have the same ingredient, semaglutide, are all the rage ever since entrepreneur Elon Musk tweeted about it.

Live updates from the Time 100 Gala 2024 red carpet and ceremony with Patrick Mahomes, Dua Lipa, Kylie Minogue, E. Jean Carroll & more.

Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.

The drugmaker was on its knees when Sir Pascal Soriot took over in 2012. But under his leadership it now does just about everything the UK wants from a business - creating high value-added jobs and developing products that improve peoples lives.

Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.

The pharmaceutical group is asking its shareholders to approve a performance-based deal that could hand Pascal Soriot (pictured) up to £18.7m this year.

The pharmaceutical group is asking its shareholders to approve a performance-based deal that could hand Pascal Soriot (pictured) up to £18.7m this year.